Sera Prognostics (SERA) Return on Capital Employed (2021 - 2026)
Sera Prognostics (SERA) reported Return on Capital Employed of 49.27% for Q1 2026, up 184.0% on a YoY basis from 17.35% in Q1 2025, and down 9.1% quarter-over-quarter from 45.16% in Q4 2025.
Sera Prognostics (SERA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Sera Prognostics has reported Return on Capital Employed for 6 years, with the latest figure at 49.27% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 184.0% year-over-year to 49.27%; the trailing twelve-month figure through Mar 2026 stood at 49.27% (up 184.0% YoY), and the FY2025 full-year result was 57.88%, up 396.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 49.27%, down from 45.16% in the prior quarter.
- The five-year high for Return on Capital Employed was 31.1% in Q1 2022, with the low at 71.81% in Q4 2024.
- Historically, Return on Capital Employed has averaged 49.31% across 5 years, with a median of 49.27% in 2026.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 2031 bps — and 2025, when it soared 2665 bps.
- Sera Prognostics' Return on Capital Employed stood at 45.24% in 2022, then declined by 29 bps to 58.3% in 2023, then decreased by 23 bps to 71.81% in 2024, then jumped by 37 bps to 45.16% in 2025, then slipped by 9 bps to 49.27% in 2026.
- The last three Return on Capital Employed figures came in at 49.27% (Q1 2026), 45.16% (Q4 2025), and 42.75% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 7.36% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 11.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 10.45% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 24.24% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 9.30% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 11.57% |
| 10 | Sera Prognostics | 93.48 Mn | 93.48 Mn | -28,000.00 | -49.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.27% |
| Dec 31, 2025 | -45.16% |
| Sep 30, 2025 | -42.75% |
| Jun 30, 2025 | -40.32% |
| Mar 31, 2025 | -51.11% |
| Dec 31, 2024 | -71.81% |
| Sep 30, 2024 | -62.44% |
| Jun 30, 2024 | -56.51% |
| Mar 31, 2024 | -55.20% |
| Dec 31, 2023 | -58.30% |
| Sep 30, 2023 | -51.85% |
| Jun 30, 2023 | -51.05% |
| Mar 31, 2023 | -45.98% |
| Dec 31, 2022 | -45.24% |
| Sep 30, 2022 | -42.61% |
| Jun 30, 2022 | -37.53% |
| Mar 31, 2022 | -31.10% |
| Dec 31, 2021 | -24.94% |
| Sep 30, 2021 | -22.84% |